Targeted discovery proteomics in cardiovascular clinical trials

Written by Olink | Jan 27, 2022 1:00:37 PM

Speakers: Christopher R. deFilippi, M.D. (Vice-Chairman of Academic Affairs at Inova Heart and Vascular Institute)

Original Broadcast date: October 28, 2021

Different pathophysiologies can trigger heart failure, which is characterized by an early, asymptomatic stage. In this video, Dr. deFilippi describes targeted discovery proteomics studies using various Olink® Target 96 panels to identify protein biomarkers indicative of pre-heart failure that can drive the development of drugs that can interrupt processes leading to heart failure. Olink® PEA technology was also used to study the proteomic changes following treatment with Vericiguat, a medication used to reduce the risk of cardiovascular death and heart failure.

The webinar covers the following points:

A review of three previous studies using a targeted proteomics approach to understand heart failure
Known biomarkers of malignant left ventricular hypertrophy (LVH) were identified
Novel biomarkers of malignant LVH were identified, many of which are involved in cardiac function or the inflammatory process
Vericiguat stimulated a unique protein profile compared to placebo controls

If you have any questions about Olink, please contact us at info@olink.com.

View full post